Chukwudum Uche, MD
Infectious Disease · Las Vegas, NVNPI 1528276052
Payments from drug & device makers
Across 621 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- AbbVie$2K
- Gilead$1K
- Astellas Pharma US Inc$1K
- Merck$1K
- Melinta Therapeutics, LLC$545
- plus $4K from 27 others
What the payments were for
- Food & beverage$11,49791%
- Education$1,0829%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 144 | $2,633 |
| AbbVie(2 entities) | 96 | $1,891 |
| Gilead | 82 | $1,438 |
| Astellas Pharma US Inc | 37 | $1,261 |
| Merck | 62 | $1,101 |
| Melinta Therapeutics, LLC | 26 | $545 |
| Johnson & Johnson(2 entities) | 31 | $504 |
| Paratek Pharmaceuticals, Inc. | 29 | $478 |
| Shionogi Inc | 19 | $457 |
| Insmed, Inc. | 13 | $274 |
| Pfizer | 6 | $207 |
| Janssen Products, LP | 2 | $200 |
| Grifols USA, LLC | 8 | $196 |
| Theratechnologies Inc. | 7 | $196 |
| Regeneron Healthcare Solutions, Inc. | 6 | $178 |
| Napo Pharmaceuticals Inc | 11 | $169 |
| Baxter Healthcare | 5 | $119 |
| Ferring Pharmaceuticals Inc. | 5 | $84 |
| GSK | 3 | $78 |
| Electromed, Inc. | 6 | $77 |
| Sanofi | 3 | $75 |
| Philips North America LLC | 3 | $70 |
| La Jolla Pharmaceutical Company | 2 | $61 |
| Janssen Scientific Affairs, LLC | 2 | $43 |
| Dynavax Technologies Corporation | 3 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| United Therapeutics Corporation | 1 | $26 |
| T2 Biosystems, Inc. | 1 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Leadiant Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,578 in reported general payments places this provider in the 80th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 34 | $19,242 |
| CeftriaxoneCeftriaxone Sodium | 118 | $10,194 |
| Daptomycin | 26 | $7,234 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 33 | $4,615 |
| Meropenem | 13 | $1,870 |
| Cefepime Hcl | 13 | $1,385 |
| Doxycycline Monohydrate | 15 | $686 |
| Rifampin | 15 | $586 |
| Fluconazole | 20 | $489 |
| Cefazolin Sodium | 17 | $483 |
| CefuroximeCefuroxime Axetil | 17 | $327 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $267 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Las Vegas
- Alireza FarabiLas Vegas$2M
- Dhiresh JoshiLas Vegas$216K
- Shadaba AsadLas Vegas$107K
- Shaker ItaniLas Vegas$52K
- Dhaval ShahLas Vegas$27K
- Alka RebentishLas Vegas$23K
- Ronald ShockleyLas Vegas$13K
- John OreillyLas Vegas$8K
- Li-Chien ChenLas Vegas$8K
- Naima ZaheerLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.